TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
31 hedge funds and large institutions have $30.3M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
26% more capital invested
Capital invested by funds: $24.1M → $30.3M (+$6.18M)
24% more funds holding
Funds holding: 25 → 31 (+6)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$4.97M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$4.97M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$1.99M |
| 4 |
AIC
AWM Investment Company
New York
|
+$1.28M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$571K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$165K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$83K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$45.7K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$41.1K |
| 5 |
SI
SII Investments
Appleton,
Wisconsin
|
-$36.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| $23K | -$2.29K | -2 | -8% |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $9K | +$4.57K | +4 | +80% |
|
|
BA
28
BlackRock Advisors
Wilmington,
Delaware
| $7K | – | – | – |
|
|
BIM
29
BlackRock Investment Management
Wilmington,
Delaware
| $7K | – | – | – |
|
30
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $4K | – | – | – |
|
|
BJ
31
BlackRock Japan
Tokyo,
Japan
| $2K | – | – | – |
|
|
32
Wells Fargo
San Francisco,
California
| – | -$83K | -63 | Closed |
|
33
Morgan Stanley
New York
| – | -$20K | -15 | Closed |
|
TCON Hedge Fund Activity: Q4 2016 in Review
31 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q4 2016, worth a combined $30.3M — up 26% from $24.1M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new TCON positions and 2 closed out — a net gain of 6 holders — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Franklin Resources, opening a new position worth an estimated $4.97M. The largest seller was Vanguard Group, cutting an estimated $165K.
- 31 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q4 2016, up from 25 in Q3 2016.
- Funds reported $30.3M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q4 2016, up 26% quarter-over-quarter.
- 8 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q4 2016 and 2 closed out, a net change of +6 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q4 2016 was Franklin Resources, an estimated $4.97M added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q4 2016 was Vanguard Group, an estimated $165K sold.
Based on aggregated 13F filings for Q4 2016.